EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Sold by Laurion Capital Management LP

Laurion Capital Management LP lowered its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 55.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 205,578 shares of the company’s stock after selling 254,428 shares during the quarter. Laurion Capital Management LP owned about 0.30% of EyePoint Pharmaceuticals worth $1,532,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Barclays PLC boosted its holdings in EyePoint Pharmaceuticals by 410.4% in the third quarter. Barclays PLC now owns 245,045 shares of the company’s stock valued at $1,959,000 after purchasing an additional 197,033 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in EyePoint Pharmaceuticals by 1,171.3% in the third quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company’s stock valued at $2,970,000 after purchasing an additional 342,516 shares during the last quarter. abrdn plc purchased a new position in EyePoint Pharmaceuticals in the fourth quarter valued at about $1,719,000. Rhumbline Advisers boosted its holdings in EyePoint Pharmaceuticals by 16.1% in the fourth quarter. Rhumbline Advisers now owns 89,560 shares of the company’s stock valued at $667,000 after purchasing an additional 12,443 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in EyePoint Pharmaceuticals in the fourth quarter valued at about $76,000. Institutional investors and hedge funds own 99.41% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on EYPT. Chardan Capital reduced their price target on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a “buy” rating for the company in a report on Thursday. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Finally, StockNews.com raised EyePoint Pharmaceuticals to a “sell” rating in a report on Friday, March 14th. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, EyePoint Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.29.

EyePoint Pharmaceuticals Stock Down 4.8%

NASDAQ:EYPT opened at $5.81 on Monday. The business’s 50 day moving average is $6.02 and its two-hundred day moving average is $7.49. EyePoint Pharmaceuticals, Inc. has a 52 week low of $3.91 and a 52 week high of $13.99. The company has a market cap of $399.79 million, a PE ratio of -2.91 and a beta of 1.58.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, May 7th. The company reported ($0.65) EPS for the quarter, hitting analysts’ consensus estimates of ($0.65). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The company had revenue of $24.50 million for the quarter, compared to the consensus estimate of $8.84 million. As a group, sell-side analysts expect that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.